Vitality Watch

Dossier rss preclinical 11-nov-2026
Animal model, organoid, or cell-culture result — not yet human

Lysergic Acid Diethylamide Induces Transcriptional Changes Opposing Signatures of Brain Ageing and Neurodegeneration

Key claim: Lysergic acid diethylamide (LSD) induces transcriptional profiles in the brain that oppose molecular signatures of aging and neurodegeneration.

Abstract

Aging Cell, Volume 25, Issue 11, November 2026.

Why this matters

[mechanism-plausible] This finding adds a molecular rationale to psychedelic healthy-aging research, but opposing an aging-associated gene-expression signature is not equivalent to reversing brain aging or preventing neurodegenerative disease. [mechanism-plausible] It extends the page’s mechanistic evidence record without establishing human benefit or safety; the finding supplies no media/community evidence with which to assess trend momentum.

Source

Link

Briefing card

Lysergic Acid Diethylamide Induces Transcriptional Changes Opposing Signatures of Brain Ageing and Neurodegeneration
Stage: preclinical · rss · 11-nov-2026

If you encounter LSD promoted for brain aging, this finding concerns preclinical gene-expression patterns, not demonstrated cognitive benefits in people.

Lysergic acid diethylamide (LSD) induces transcriptional profiles in the brain that oppose molecular signatures of aging and neurodegeneration.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: url:https://onlinelibrary.wiley.com/doi/10.1111/acel.70793?af=R

build build 880 · 2bcef25 · 2026-11-18